0000000000794064

AUTHOR

Holger Sültmann

0000-0002-5257-8600

showing 2 related works from this author

Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue.

2010

Abstract Background Cell lines play an important role for studying tumor biology and novel therapeutic agents. Particularly in pulmonary squamous cell carcinoma (SCC) the availability of cell lines is limited and knowledge about their representativeness for corresponding tumor tissue is scanty. Materials and methods We established three novel SCC cell lines from fresh tumor tissue of 28 donors, including 8 SCC. Two cell lines were derived from different localizations of the same donor, i.e. primary tumor and lymph node metastasis. This represents a so far unique combination in lung cancer. The genotypes, gene expression profiles and mutational status of epidermal growth factor receptor ( EG…

Pulmonary and Respiratory MedicineCancer ResearchLung NeoplasmsAngiogenesisCarcinogenicity TestsCellIn situ hybridizationCell Growth ProcessesBiologymedicine.disease_causeMiceCell MovementCarcinoma Non-Small-Cell LungCell Line TumormedicineCell AdhesionAnimalsHumansCell LineageIn Situ Hybridization FluorescenceMutationComparative Genomic Hybridizationmedicine.diagnostic_testNeovascularization PathologicGene Expression ProfilingCell Differentiationmedicine.diseasePrimary tumorMolecular biologyDNA FingerprintingGene expression profilingErbB Receptorsmedicine.anatomical_structureGenes rasOncologyCell cultureTandem Repeat SequencesLymphatic MetastasisMutationCarcinoma Squamous CellFluorescence in situ hybridizationLung cancer (Amsterdam, Netherlands)
researchProduct

The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer

2007

Antibody-based cancer immunotherapy relies on the identification and characterization of target antigens and the development of potent antibodies recognizing the target. Here we report the expression analysis and molecular characterization of the differentiation antigen NY-BR-1, which we previously identified by using the SEREX (serological analysis of recombinant cDNA expression libraries) method. Corroborating methodologies, including mRNA quantitation and immunoblotting show that NY-BR-1 is strongly expressed in >70% of 129 breast tumors. Application of a NY-BR-1 specific antibody demonstrated NY-BR-1 expression in primary and metastastic breast cancers. In contrast, most of the breast c…

CytoplasmCancer ResearchPathologymedicine.medical_specialtyRecombinant Fusion Proteinsmedicine.medical_treatmentCellular differentiationGreen Fluorescent ProteinsImmunoblottingBreast NeoplasmsBiologyTargeted therapyBreast cancerAntigenCancer immunotherapyAntigens NeoplasmCell Line TumormedicineHumansRNA MessengerBinding SitesMicroscopy ConfocalReverse Transcriptase Polymerase Chain ReactionCell MembraneAntibodies MonoclonalMembrane ProteinsFlow Cytometrymedicine.diseaseAntigens DifferentiationImmunohistochemistryTumor antigenGene Expression Regulation NeoplasticOncologyCancer researchbiology.proteinImmunohistochemistryFemaleAntibodyHydrophobic and Hydrophilic InteractionsInternational Journal of Cancer
researchProduct